Discounted Cash Flow (DCF) Analysis Levered
Anixa Biosciences, Inc. (ANIX)
$3.75
+0.24 (+6.84%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 0.25 | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -4.74 | - | - | - | - | - | - | - | - | - |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -0.18 | - | - | - | - | - | - | - | - | - |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -4.92 | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
Share price | $ 3.75 |
---|---|
Beta | 0.857 |
Diluted Shares Outstanding | 30.98 |
Cost of Debt | |
Tax Rate | 1.20 |
After-tax Cost of Debt | 4.94% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 8.360 |
Total Debt | 0.17 |
Total Equity | 116.17 |
Total Capital | 116.35 |
Debt Weighting | 0.15 |
Equity Weighting | 99.85 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 0.25 | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -4.74 | - | - | - | - | - | - | - | - | - |
Capital Expenditure | -0.18 | - | - | - | - | - | - | - | - | - |
Free Cash Flow | -4.92 | - | - | - | - | - | - | - | - | - |
WACC | ||||||||||
PV LFCF | - | - | - | - | - | - | - | - | - | |
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 8.35 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -0.74 |
Equity Value | - |
Shares Outstanding | 30.98 |
Equity Value Per Share | - |